Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 11:35:28 2024-04-25 am EDT			5-day change	1st Jan Change
150.1 ^EUR	-1.48%		+1.97%	+4.16%

Apr. 25	Scholz pledges further support for the pharmaceutical industry	DP
Apr. 25	Scholz promises support for pharma sector in Germany as Merck invests	RE

MERCK KGAA : UBS reiterates its Neutral rating

May 18, 2021 at 06:30 am EDT

In a research note published by Michael Leuchten, UBS gives a Neutral rating to the stock. The target price is unchanged at EUR 136.

Latest news about Merck KGaA

Scholz pledges further support for the pharmaceutical industry	Apr. 25	DP
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
Merck KGaA Starts Building EUR300 Million Life Science Research Center in Germany	Apr. 25	MT
Scholz visits Merck and Family Business Days	Apr. 24	DP
US competitor Danaher boosts Merck KGaA and Sartorius	Apr. 23	DP
MERCK KGAA : Barclays reiterates its Buy rating	Apr. 19	ZD
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Agronomics Portfolio Company Mosa Meat Raises EUR40 Million to Beef Up Production	Apr. 17	MT
Merck KGaA Rolls Out New Genetic Stability Assay Platform	Apr. 16	MT
MERCK : A peer group tidy up	Apr. 13
Merck Announces Change of Managing Director of Merck Life Science in India	Apr. 09	CI
Caris Life Sciences Announces Partnership with Merck KGaA to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 04	CI
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI
UBS Raises Merck KGaA PT, Keeps Buy Rating	Mar. 26	MT
MERCK KGAA : Jefferies keeps its Buy rating	Mar. 26	ZD
MERCK KGAA : price target raised by UBS	Mar. 26	CF
MERCK KGAA : Buy rating from UBS	Mar. 26	ZD
Merck KGaA to Open $326 Million Pharmaceutical Plant in South Korea to Expand in Asia	Mar. 20	DJ
Merck KGaA Spends EUR300 Million on New Bioprocessing Site in South Korea	Mar. 20	MT
MERCK KGAA : DZ Bank gives a Buy rating	Mar. 20	ZD
MERCK KGAA : JP Morgan gives a Buy rating	Mar. 18	ZD
MERCK KGAA : Barclays gives a Buy rating	Mar. 12	ZD
Deutsche Bank raises target for Merck KGaA to 175 euros - 'Buy'	Mar. 12	DP
MERCK KGAA : Deutsche Bank remains its Buy rating	Mar. 12	ZD
MERCK : A weak finish but the 2024 guidance leaves room for positives	Mar. 08

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

MERCK : A peer group tidy up

April 13, 2024 at 04:06 pm EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST

More Strategies

Ratings for Merck KGaA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

152.4 EUR

Average target price

182 EUR

Spread / Average Target

+19.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+4.16%	70.78B
KYOWA KIRIN CO. LTD.	+10.72%	9.15B
SK BIOPHARMACEUTICALS CO., LTD.	-17.03%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+37.51%	4.22B
YUHAN CORPORATION	+3.92%	3.92B
INDIVIOR PLC	+18.14%	2.55B
BETTA PHARMACEUTICALS CO., LTD.	-24.13%	2.26B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.70%	2.24B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+9.09%	1.92B
SUPERNUS PHARMACEUTICALS, INC.	+1.28%	1.66B

Specialty & Advanced Pharmaceuticals

Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

MERCK KGAA : UBS reiterates its Neutral rating

Latest news about Merck KGaA

Chart Merck KGaA

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Merck KGaA

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals